Book details

Book description

Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation.
The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the development pipeline of major pharmaceutical companies to illustrate the power and potential of this approach. Alexander Domling studied Chemistry and Biology at the Technical University Munich, Germany. After obtaining his PhD under the supervision of Ivar Ugi, he spent a postdoctoral year at the Scripps Research Institute in La Jolla (USA) in the group of Nobel Laureate Barry Sharpless. In 2004 he performed his habilitation at the Technical University of Munich. Since 2006 he is associate professor at the University of Pittsburgh in the Department of Pharmacy with secondary appointments in Chemistry and Computational Biology. Dr. Domling is founder of several biotech companies, including Morphochem and R&D Biopharmaceuticals. His research centers around the discovery of antagonists of protein-protein interactions in the therapeutic areas of oncology, infectious and neglected tropical diseases.